Improving Substance Use Disorder Treatment During and After the COVID-19 Pandemic

Access to effective substance use disorder (SUD) treatment has long been out of reach for many. The COVID-19 pandemic has forced treatment providers and clients to limit in-person interaction, reducing longstanding barriers to treatment for some, but increasing challenges for others.

This is the third in a series of seven discussions that DPA held on COVID-19 and drug policy. These discussions bring together advocates and allies in the justice reform movement to discuss how we can sustain progress, which obstacles still remain, and how we can use the current moment to be more aspirational with our policy agendas.


  • Dr. Anjali Taneja, MD, MPH, Casa de Salud New Mexico
  • Dr. Kima Taylor, MD, MPH, Anka Consulting LLC
  • Dr. Lisa Puglisi, MD, Yale University, Transitions Clinic-New Haven
  • Dr. Richard Rawson, PhD, University of California Los Angeles, University of Vermont
  • Dr. Roopa Sethi, MD, University of Kansas

Moderator Kellen Russoniello, Drug Policy Alliance

Watch more of this discussion series.

Drug Treatment